BV 5200

Drug Profile

BV 5200

Alternative Names: Cardiclear; HYAL BV5200

Latest Information Update: 19 Dec 2006

Price : $50

At a glance

  • Originator SkyePharma Inc
  • Class Anti-ischaemics
  • Mechanism of Action CD44 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Coronary artery restenosis

Most Recent Events

  • 17 Dec 1998 Suspended-II for Coronary artery restenosis in Canada (IV)
  • 29 May 1995 Preclinical development for Coronary artery restenosis in United Kingdom (IV)
  • 29 May 1995 Phase-I clinical trials for Coronary artery restenosis in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top